Local application of THIO-TEPA in the prevention of recurrent papillary carcinoma of the bladder.
Prophylactic total THIO-TEPA treatment was employed in 44 cases over a period of five years, following radical surgery (including reoperations) for recurrent vesical papillomatosis or carcinoma, and numerous subsequent transurethral coagulations or resections owing to multiple recurrences. Three patients have been now free from recurrences for five years, 13 patients for four years, 11 patients for three years and 9 patients for two years. Eight patients proved unresponsive, the recurrence rate having remained unaffected. No toxic effects requiring any special measures were encountered.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D013852:Thiotepa / Q000008:administration & dosage* / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
D013852:Thiotepa